Viral Genetics, Inc., has entered into license agreements for discoveries resulting from Newell's work at CU. Haig Keledjian, president of Viral Genetics (OTC:VRAL.PK), said of the newly formed collaboration, "We now have the resources of two leading universities behind our research team. This joint effort will provide Dr. Newell's very important work with the support it deserves. Since we licensed Dr. Newell's technology years ago, we have witnessed many breakthroughs. With her extraordinary ability, we have very high hopes of developing treatments for the multiple diseases she is working on. We are 100 percent behind Dr. Newell and this collaboration that offers increased hope for people with many debilitating and life-threatening diseases."

Keledjian also announced Viral Genetics' intention to establish a physical presence in both Colorado Springs and Georgetown, Texas, to support the continued collaborative and individual research efforts of the two institutions.

Headquartered in San Marino, Calif., Viral Genetics discovers and develops drug therapies to treat infectious, autoimmune and immunological deficiency disorders using its targeted peptide technology (TPT), metabolic disruption technology (MDT) and thymus nuclear protein compound (TNP). Viral Genetics has optioned the exclusive right to develop any and all drug therapies based on TPT and MDT technology through an agreement with the University of Colorado and V-Clip Pharmaceuticals (a Viral Genetics subsidiary.) Viral Genetics has formed a wholly owned subsidiary, MetaCytoLytics, Inc, to advance its research into MDT.

SOURCE Texas A&M Health Science Center